| Catalog | name | Description | price |
|---|---|---|---|
| R-XASYS-00587 | Abaperidone,cas:183849-43-6 | Abaperidone(C25H25FN2O5,452.5) is an antipsychotic. Reduced hsp70 in the prefrontal cortex may play a critical role in the etiology of many schizophrenia symptoms and may be linked to an atypical profile of antipsychotics, such as abaperidone. | price> |
| R-XASYS-00588 | ABBV-744,cas:2138861-99-9 | ABBV-744(C28H30FN3O4,491.6) is an inhibitor of the bromodomain and extra-terminal domain (BET) family protein bromodomain 2 (BD2; Kis = 4.6, 4.9, 1.6, and 1 nM for BRD2, -3, -4, and -T, respectively).ABBV-744 inhibits proliferation of SKM-1 leukemia cells (IC50 = 6.7 nM). | price> |
| R-XASYS-00589 | ABT-072,cas:1132936-00-5 | ABT-072( C24H27N3O5S,469.55) is a HCV NS5B polymerase inhibitor potentially for the treatment of HCV infection. | price> |
| R-XASYS-00590 | Ac-Leu-Arg-AMC,cas:929621-79-4 | Ac-Leu-Arg-AMC(C24H34N6O5,486.56)is a fluorogenic peptide substrate. | price> |
| R-XASYS-00591 | AC260584,cas:560083-42-3 | AC-260584(C20H29FN2O2,348.5) is an orally bioavailable M(1) muscarinic receptor allosteric agonist. | price> |
| R-XASYS-00592 | N-(p-amylcinnamoyl) Anthranilic Acid,cas:110683-10-8 | N-(p-amylcinnamoyl) Anthranilic acid (ACA)(C21H23NO3,337.4) is a channel blocker that acts on several transient receptor potential (TRP) channels, including TRPM2, TRPM8, and TRPC6 (IC50 = 1.7, 3.8, and 2.3μM, respectively). | price> |
| R-XASYS-00593 | ACAT-IN-10,cas:454203-40-8 | ACAT-IN-10(C35H56N4O5S,644.91) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 197. ACAT-IN-10 weakly inhibits NF-κB mediated transcription. | price> |
| R-XASYS-00594 | ACAT-IN-4 hydrochloride,cas:199984-46-8 | ACAT-IN-4 hydrochloride (Example 208)(C32H51ClN2O5S,611.28) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-4 hydrochloride inhibits NF-κB mediated transcription. | price> |
| R-XASYS-00595 | ACAT-IN-9,cas:199984-40-2 | ACAT-IN-9(C33H51N3O5S,601.84) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 207. ACAT-IN-9 inhibits NF-κB mediated transcription. | price> |
| R-XASYS-00596 | Acelarin,cas:840506-29-8 | Acelarin(C25H27F2N4O8P,580.5) is a novel small molecule that has recently been identified as a promising new therapeutic agent for the treatment of various diseases. Acelarin was first identified in 2015 as a small molecule inhibitor of the enzyme, cyclin-dependent kinase 4 (CDK4). | price> |

Items-$0.00

Email:
Tel.:
RuixiBiotechCo.Ltd /KamulinBiotechco.ltd
Add: Room 20F 2002, Meiyuan Building, Yanta District, Xi’ an City, Shaanxi Province 710061 China
Tel: 02988811435
Fax: (86-29)8881-1435
Email: sales@ruixibiotech.com
Web: http://www.ruixibiotech.com


